The 15th Tumour Models London 2026 is a conference that explores advanced tumour models, including patient-derived, humanised, and preclinical systems, to enhance cancer therapy development and translational research.
Key Topics
Patient-derived tumour spheroids and organ-on-a-chip models
Humanised mouse models for T cell and CAR-T therapy development
Genetically engineered mouse models (GEMMs) for cancer pathogenesis and resistance
Optimising translational relevance of preclinical tumour models
Advancing ADC, peptide drug conjugates, and small molecule therapies
Preclinical strategies for T-cell engagers and immunotherapies
Mathematical and in silico modelling for therapeutic development
Organoids and PDX platforms for adaptive cancer therapy responses
Consensus-building on model selection criteria across modalities
Alternatives to animal models and compliance with regulatory updates
Who should Attend
Researchers and scientists in oncology and translational medicine
Preclinical and clinical development professionals
Pharmaceutical and biotech industry representatives
Pathologists and immunotherapy developers
Academics focused on tumour modelling and cancer therapy research
Regulatory affairs specialists and drug development strategists
